Cite

HARVARD Citation

    Maio, M. et al. (n.d.). P863 KEYNOTE-022 parts 4 and 5: pembrolizumab plus trametinib for patients with solid tumors or BRAF wild-type melanoma. Journal for immunotherapy of cancer. pp. A10-A11. [Online]. 
  
Back to record